Why Did NTLA Stock Jump 10% Today?

• The hold was placed in October 2025 after a patient experienced severe liver-related side effects.
• The company has agreed with the FDA on closer monitoring of liver function, short-term steroid treatment if needed, and stricter patient screening.
• MAGNITUDE is set to study about 1,200 patients to evaluate the safety and effectiveness of a single dose of nex-z compared to placebo.

Shares of Intellia Therapeutics (NTLA) surged more than 10% on Monday after the company announced that the U.S. Food and Drug Administration (FDA) lifted a clinical hold on its Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a potentially fatal heart condition.

The hold was placed in October 2025 after a patient experienced severe liver-related side effects. The company has now agreed with the FDA on new safety measures, including closer monitoring of liver function, short-term steroid treatment if needed, and stricter patient screening. Some patients with liver issues or serious heart instability will be excluded.

“With the resolution in January of the clinical hold on our MAGNITUDE-2 Phase 3 trial for patients with hereditary ATTR with polyneuropathy, our attention now turns to completing enrollment in both ongoing trials. We appreciate the FDA’s responsiveness throughout this process and thank the many investigators and patients who are participating in these trials," said President and CEO, John Leonard.

MAGNITUDE Study 

MAGNITUDE is set to study about 1,200 patients to evaluate the safety and effectiveness of a single dose of nex-z compared to placebo. MAGNITUDE-2 is a randomized, double-blind, placebo-controlled study testing nex-z in about 60 adults with hereditary ATTR amyloidosis affecting the nerves (ATTRv-PN). 

Patients are randomly assigned to receive either a single 55 mg infusion of nex-z or a placebo. The study’s main goals are to track changes in nerve function using a neuropathy score and changes in blood TTR levels to see if the treatment is effective and safe.

How Did Stocktwits Users React?

Retail sentiment for NTLA on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.  

One user expects the stock to hit $20. It is trading around $15.4 at the time of writing.

Another user said the stock is still 'ridiculously cheap.' 

Year-to-date, the stock has gained around 65%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.